Navigation Links
Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO

/p>

Algeta is developing new, targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.

Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.

Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.

The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).

Alpharadin and Algeta are trademarks of Algeta ASA.

Forward-looking Statement

This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of operations and the financial condition of Algeta. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Theses factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to close viable and profitable business deals, the risk of non-approval of patents not yet granted and difficulties of obtaining relevant governmental approvals for new products


'"/>




Page: 1 2

Related medicine technology :

1. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:9/19/2014)... Five MinuteClinic walk-in medical clinics are opening inside select CVS/pharmacy stores ... opened in Memphis and Cordova ... in Springfield on September 24 and a ... open October 22.  MinuteClinic is the largest and fastest growing provider ... . The Memphis -area clinics join ...
(Date:9/19/2014)... 19, 2014  Lpath, Inc. (NASDAQ: ... therapeutics, announced today that it has entered into ... common stock and 3,605,042 unregistered warrants in a ... one registered share of common stock and one ... common stock will be $3.475.  The warrants have ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 23 Reportlinker.com announces that a new market research ... Eli Lilly & Co.: PharmaVitae Profile ... analysis examines the historical and forecast performance for Eli ... global company strategy, portfolio and pipeline analysis and assessment ...
... Sept. 23 As technologies for fat removal become ... not only reshaping the body but also recycling the ... to the most recent statistics from the American Society ... are among the two most popular invasive and non-invasive ...
Cached Medicine Technology:Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 2Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 3Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 4Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 5Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 6Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile 7The New Face of Body Contouring 2
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... More than 60 new GranuFlo ... the past month to a federal multidistrict litigation ... caused by the dialysis concentrate, Bernstein Liebhard LLP ... 15th shows 2,089 cases filed in a federal ... of Massachusetts. These claims were filed on behalf ...
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ ... resolve,” said Steve Young of Ew Publishing; “I’ve had ... that is more intense.” , “It should be a ... migraines, that medical research is pointing to some relief ... , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found ...
(Date:9/21/2014)... Developers and plugin specialist of Final ... transition plugin entitled Transpack Vol. 3 from Pixel Film ... that will add a level of professionalism to any ... Film Studios. “Blurring the line between professional and armature, ... Transpack Vol. 3 returns with over 85 all new ...
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4
... to a report published in the October issue of ... , a grant-funded program tailored to provide advanced minimally ... helping address shortages of minority faculty members at US ... Diverse Surgeons Initiative (DSI) has helped 86 percent of ...
... Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) ... Radiology Imaging Network (ACRIN) and European Society of Breast ... study in the November issue of the Journal of ... BCSC is a collaborative effort to improve breast cancer ...
... Oct. 30 (HealthDay News) -- Hepatitis C patients who receive ... recurrent hepatitis than those who receive a liver from a ... for black patients who receive a liver from a white ... Hospital in Detroit looked at 165 hepatitis C patients who ...
... Kan. A little self-awareness can help people struggling ... professor of communication studies at the University of Kansas. ... flirting among dating adults, surveying more than 5,100 people ... "Knowing something about the way you communicate attraction says ...
... , SUNDAY, Oct. 31 (HealthDay News) -- Heat ... cool environments, a new study has found. University ... underwent a 10-day heat acclimation program achieved increases of ... and cool conditions. In terms of competitive cycling, this ...
... Reporter , FRIDAY, Oct. 29 -- A good marriage ... life and experience less pain, a new study suggests. ... that seems to buffer a patient,s emotional health," said ... the Johns Hopkins University School of Medicine in Baltimore. ...
Cached Medicine News:Health News:Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery 2Health News:Majority of community facilities performing breast MRI exams meet ACRIN and EUSOBI technical requirements 2Health News:Self awareness can help people navigate rocky seas of relationships 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 2Health News:Good Marriages May Help Rheumatoid Arthritis Patients 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: